Tessa Therapeutics’ closure due to increasing interest rate and unsustainable revenue
Tessa Therapeutics’ liquidation results from a tighter monetary policy and a surge in global interest rates, according to investor Ian Yoong Kah Yin. The closure of the Temasek-backed company leaves a significant impact on Singapore’s biotech industry.
